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Innate immunity to tumors is mediated mainly by natural killer cells (NKs) and dendritic cells (DCs). The
function of these cells is coordinated by cytokines produced during the inﬂammatory process. NK cells
are highly active against tumors, being an important source of IFN-c. Natural killer dendritic cells
(NKDCs) were recently identiﬁed as a group of hybrid cells; some studies claim that they have lytic activ-
ity, produce IFN-c and can also stimulate antigen-speciﬁc T cells. Interleukin 21 (IL-21) regulates the pro-
liferation capacity and cytotoxicity of NK and T cells. The main objective of this study was to investigate if
IL-21 inﬂuences the frequency of NKDCs in vitro as well as IFN-c production and also to verify if these
cells could enhance the antitumor activity against B16F10 tumor model in vivo. Splenocytes from
C57BL/6 mice were isolated and the DC were enriched by immunomagnetic beads and cultured for four
days with recombinant IL-21 (10, 20, 40 or 100 ng/ml). NKDC population was characterized as CD11clow/
medB220+NK1.1+. Expanded cells were used to treat B16F10 tumor bearing mice and tumor growth was
compared between the doses of IL-21 10 ng/ml and 20 ng/ml. The results indicate that IL-21 increases
the expansion of splenic NKDCs in vitro in doses of 10 ng/ml and 20 ng/ml and these cells produce
IFN-c. In vivo, cells expanded with IL-21 and injected directly into the growing tumor efﬁciently reduced
the tumor size. Together, these results showed for the ﬁrst time that IL-21 inﬂuences the biology and the
effector activity of NKDCs.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
One of the main effective responses against tumor cells is cyto-
toxicity [1,2]. This response is provided mainly by CD8+ T lympho-
cytes and natural killer cells (NKs) [3–5]. NK cells are components
of innate immunity acting as killers of target cells independently of
TCR stimulation and producing IFN-c [6], while CD8+ T lympho-
cytes belong to adaptive immunity and kill tumor cells after anti-
gen recognition on MHC class I molecules [7,8]. The cytotoxicity
of both NK cells and CD8+ T lymphocytes is mediated by granzymes
and perforines, and IFN-c secretion is also increased during the
activity of both cells [9]. Recently, a new group of cells was identi-
ﬁed with the ability of killing, producing IFN-c, and probably anti-
gen presentating capacity. These cells were called natural killer
dendritic cells (NKDCs) [10] or IFN-c producing dendritic cells
(IKDCs) [11]. NKDCs can be found in lymphoid and non-lymphoid
organs and are highly stimulated in presence of CpG to secrete IFN-
c and lyse speciﬁc target cells [12]. They represent 1–2% of spleen
derived CD11c+ cells in unmanipulated C57BL/6 mice (no tumor or
infection) [13]. Very low numbers of NKDCs are isolated from mice
without any speciﬁc enrichment treatment. Some authors have
considered the use of molecules such as CpG, IL-15, IL-18 and55 32226484.
igues Jr.).
sevier OA license.Flt3 to expand NKDCs in vivo or in vitro. The synergistic action of
CpG plus IL-18 in vivo increases by about 6-fold the number of
splenic NKDC, in which 90% of cells produce IFN-c, and this mech-
anism is dependent on autocrine action of IL-12 produced by NKDC
[14].
Interleukin-15 knockout mice lack NKDCs, however this
population can be restored with exogenous administration of re-
combinant IL-15; after this treatment, cells exhibit expressive
anti-tumor activity, even higher than NK cells [15]. Interleukin-
21 (IL-21) belongs to the same cytokine family as IL-15 (common
c-chain receptor users) that induces proliferation of lymphocytes
[16]. IL-21 is mainly produced by activated CD4+ T cells [17] and
has a pivotal role in NK cell effector function [18–20]. Murine NK
cells upon IL-21 stimulation improve the IFN-c production and
killing activity in tumor mouse models [21]. Treatment of human
NK cells with IL-21 increases the expression of anti-apoptotic pro-
teins such as BcL-2 and BcL-x(L) and enhances viability of NK cells,
without substantial effects on proliferation [22]. This cytokine has
been intensively investigated for development and optimization of
vaccines and immunotherapy against tumors, mostly based on NK
cell induction and activation.
Considering the dependence of NKDC to other cytokines from
family of c chain receptor users, specially IL-15, and the high
inﬂuence of IL-21 on NK cells biology, we hypothesized that the
recombinant IL-21 would have an effect on NKDC frequency and
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ically the frequency of NKDC cells in vitro and these cells also pro-
duce IFN-c. After expansion with IL-21 cells presented killing
activity against B16F10 tumor cells in vitro and adoptive transfer
of NKDC cells resulted in reduction of tumor size in vivo. Collec-
tively, our results suggest that IL-21 can be applied to expand
anti-tumor NKDC IFN-c+ for use in immunotherapy against cancer.2. Methods
2.1. Mice
C57BL/6 (B6) mice were purchased from Fundação Estadual de
Produção e Pesquisa e Saúde (FEPPS) Porto Alegre, RS, Brazil. Mice
were housed under pathogen-free conditions at Pontifícia Univer-
sidade Católica do Rio Grande do Sul (PUCRS) Faculdade de Biociên-
cias (FABIO) animal facilitywith ad libitum access to food andwater.
Female six to eight week old mice were used for all experiments, in
groups of n = 5 animals and thesewere conductedwith the approval
of PUCRS’ Ethics Committee on Animal Research (CEUA).
2.2. Antibodies, proteins and reagents
Antibodies were purchased from BD Biosciences. Characteriza-
tion of NKDC population was conducted by surface staining with
Cy-Chrome conjugated anti-CD11c, ﬂuorescein isothiocyanate
(FITC) conjugated anti-B220 (CD45R) and phycoerythrin (PE) con-
jugated anti-NK 1.1. For interferon analysis, FITC conjugated anti-
IFN-c, Cy5 conjugated anti-B220, Cy7 conjugated anti-CD11c, and
PE conjugated anti-NK1.1 were used. The expression of IL-21R
was determinate using PE conjugated mouse anti-IL-21R. Flow
cytometry analysis was done on FACS Canto (BD Bioscience). Re-
combinant IL-21 and anti-IL-21 was purchased from eBioscience
(San Diego, CA, USA). The data were analyzed using FlowJo soft-
ware (Tree Star).
2.3. Cell isolation
Cellular isolation was done as previously described [12]. Brieﬂy,
animals were euthanized by CO2 inhalation and splenocytes were
isolated from spleen. After lysis of erythrocytes with cell lysis buf-
fer (8.26 g ammonium chloride; 1 g potassion bicarbonate; 0.037 g
EDTA/liter) cells were enriched based on CD11c expression with
immunonagnetic beads using the manufacturer’s protocol MAC’s
(Milteniy Biotec). The purity of preparation was analyzed in FACS
using Cy-chrome conjugated anti-CD11c antibody.
2.4. Expansion of NKDC in vitro
Cells recovered after CD11c enrichment were cultured in 24
well plate (1  106 cells/ml) using Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM – Gibco, Carlsbad, CA, USA) containing 10% fetal
bovine serum (FBS – Gibco, Carlsbad, CA, USA) Gentamicin
80 mg/l (Novafarma, Anápolis, Brazil), Fungisone – Anfotericin B,
5 mg/l (Bristol Myers Squibb, New York, NY, USA), 2 mM L-Gluta-
mine (Sigma, St. Louis, MO, USA) and 1MEM amino acid solution
(Invitrogen Corporation, Carlsbad, CA, USA). The medium was sup-
plemented with recombinant IL-21 (IL-21) or only saline. Concen-
trations of 10 ng/ml, 20 ng/ml, 40 mg/ml and 100 ng/ml of IL-21
were used for in vitro treatment, based on our previous studies
[23]. Cells were incubated in 37 C with atmosphere of 5% CO2.
Four days after culture, total cells were removed from the plate,
rinsed with PBS and stained with anti-CD11c, anti-NK1.1 and
anti-B220. The frequency of NKDCs (CD11clow/med, NK1.1+, B220+)
was compared among NKDC cultured only with DMEM/salineand IL-21 treatments. To determine, if the effects observed after
treatment of NKDC with IL-21 were speciﬁc, an antibody neutral-
ization method was used. The media described above were treated
for one hour with different concentrations of anti-murine IL-21
antibody (2, 5 or 10 lg/ml) to neutralize the IL-21 protein and
block the binding to its receptor on cells surface.
2.5. Cytokine analysis
Interferon gamma production by IL-21 treated NKDC was ana-
lyzed through intracellular staining. Brieﬂy, dendritic cells were
isolated as described in Section 2.3 and cultured with recombinant
IL-21 (10 or 20 ng/ml) in DMEM media supplemented with 10%
FBS, DMEM/saline was used as control. Four days after culture in
CO2 incubator the total expanded cells were treated with Golgi
plug (Becton and Dickson) for four hours and the cells stained.
For this analysis the total expanded cells were stained with anti-
CD11c, Cy-5 conjugated anti-B220 and anti-NK 1.1. After staining
cells were permealized and again stained with anti-IFN-c.
2.6. Tumor cell lines
B16F10 melanoma cells, a kind gift from Dr. Peter Henson
(National Jewish Center for Immunology, Denver, CO, USA) were
cultured DMEM supplemented with 10% FBS in conditions of
37 C and atmosphere of 5% CO2.
2.7. In vitro cytotoxic assay with B10F10
The in vitro cytotoxic assay was performed as previous de-
scribed by Jedema and collaborators [40]. Brieﬂy, NKDCs (effectors
cells) were enriched from a culture of dendritic cells using IL-21 as
stimuli (10 or 20 ng/ml), meanwhile cell suspension of B16F10
cells were stained with CFSE (target cells). After expansion
6  104 cells were cultured with CFSE stained B16F10 stimulated
at different ratios for four hours in CO2 incubator. The proportion
of effectors and target cells used was E/T 1:6 (1  104); 1:12
(0.5  104) and 1:24 (0.25  104).
2.8. IL-21 treatment and tumor injections
Naïve C57BL/6 mice were inoculated subcutaneously with 105
B16F10 melanoma cells in the right thigh diluted in 100 ll of phos-
phate-buffered saline (PBS). After 4 days of tumor growth1  105 IL-
21 treated CD11c enriched cells were injected subcutaneously into
the tumor site. For all animal experiments, tumor sizewasmeasured
every 3 days using a caliper. All subcutaneous injections were done
after anesthesiawith83ofmg/kgketamineand17 mg/kgofxilazine.
Micewere killed in a CO2 chamber 20 days after tumor injection. Tu-
morvolume(V) (mm3)wascalculateusingV = d2  D  0.5, inwhich
d = minor diameter and D = major diameter.
2.9. Statistical analysis
The Mann Whitney test was used to groups comparison. Statis-
tical analysis and graphs were performed using GraphPad Prism
version 4.0 (GraphPad Software, San Diego, CA). Differences with
p < 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Interleukin-21 increases the frequency of splenic NKDC in vitro
Considering previous observations about the activity of IL-21 on
NK cells, we investigated if this cytokine could also inﬂuence the
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enriched by magnetic beads sorting. NKDC cells were characterized
as CD11clow/medB220+NK1.1+. For this characterization, we gated on
CD11clow/med cells and inside this gate only cells positive for B220
and NK1.1 were selected (NKDC). NKDCs represented 0.95% from
total isolated CD11clow/med cells in a culture without any stimuli
(Fig. 1A–C). To test IL-21 as an inducer of NKDC, CD11c+ isolated
cells were counted and 1  106 cells were cultured in DMEM 1X
supplemented with IL-21 (10 ng/ml, 20 ng/ml, 40 or 100 ng/ml),
media with saline was used as control. When splenic puriﬁed
DCs were cultured in media with IL-21 (20 ng/ml), the frequency
of NKDC increased reaching a magnitude of 3.66% from the total
CD11c+, comparing with untreated cells a fold increase of 3.85
was observed (Fig. 1D). This result suggested that IL-21 can in-
crease the numbers of splenic NKDC in vitro from a bulk culture
of splenic DC. The population of CD11clow/medB220+ cells that wereFig. 1. NKDC characterization and expansion with IL-21. Isolated splenocytes from C57BL
with immunonagnetic beads. Cells were stained with CD11c FITC, B220 Cy-chrom and NK
on SSC  FSC (A), inside this population a second gate with CD11c+ cell was done (B), and
cells (1  106) were cultured with 20 ng/ml of IL-21 for four days and cells stained with th
from the total CD11c+ cells; pDCs (Circled population). (E) Puriﬁed CD11c+ cells were tr
NKDCs compared. (F) Interleukin-21 (20 ng/ml) was incubated with anti-IL-21 (2 lg,
percentage of NKDCs were analyzed. (G) Isolated splenic DCs were stained with CD11c C
the expression of IL-21R was determined in unstimulated lymphocytes (dashed); pDC
populations, lymphocytes (4.27) pDCs (10.78) and NKDCs (24.95).negative for NK1.1 (plasmacytoid DC), which also are present in
the CD11c+ puriﬁed cells, did not change frequency upon treat-
ment with any amount of IL-21 (data not shown). To investigate
if the expansion of NKDC with IL-21 is a dose dependent phenom-
enon, higher quantities of the cytokine were used. As shown in
Fig. 1E, an expansion was observed with the doses of 10 and
20 ng/ml, but decreased when higher doses were used.
Since we observed that IL-21 expands NKDC in vitro, we decided
to investigate if this is a speciﬁc phenomenon induced by this cyto-
kine. The media with IL-21 was treated for one hour with three dif-
ferent concentrations of murine anti-IL-21 antibody (2 lg/ml,
5 lg/ml or 10 lg/ml) and then added to supplement the culture
of puriﬁed CD11c+ cells. Four days after culture, NKDCs were
analyzed. As seen in Fig. 1F, the percentage of NKDC in the wells
treated with anti-IL-21 decreased compared to wells without
neutralizing treatment. The NKDC percentage decreased/6 were treated with RBC buffer and cells were enriched based on CD11c expression
1.1 PE and analyzed by FACS. The NKDC population were identiﬁed with a ﬁrst gate
ﬁnally the B220+ NK1.1+ cells were taken from CD11c+ cells (C). (D) Puriﬁed CD11c
e same antibodies used for characterization. The percentage of NKDCs reached 3.66%
eated with different doses of IL-21 (10, 20, 40 or 100 ng/ml) and the percentage of
5 lg or 10 lg) by one hour and used to culture CD11c+ cells four days after the
y7; B220 Cy-chrom; Nk1.1 FITC and IL-21R PE. Cells were analyzed using FACS and
s (tinted) and NKDCs (solid). The histogram represents the MFI from these three
A.P. Souza et al. / Cytokine 61 (2013) 154–160 157proportionally to the amount of anti-IL-21 added. Taken together
these results shows that in vitro treatment of splenic isolated
CD11c+ cells with recombinant IL-21 increases speciﬁcally the
numbers of NKDCs.
3.2. Puriﬁed NKDC express IL-21R on cell surface
Since we have shown that culture of splenic puriﬁed CD11c+
with IL-21 can increase NKDC numbers we should also consider
that this observation could be related with other bystander effect
produced by any factor released from cells in culture. To eliminate
this hypothesis we investigated if fresh NKDC from spleen ex-
presses the IL-21 receptor on surface. Again, splenic CD11+ cells
were isolated by immunonagnetic beads stained for CD11c, B220,
NK1.1 and IL-21R. The expression level of IL-21R on NKDC was
compared with the pDC population that previously did not ex-
panded with any concentration of IL-21, as negative control unac-
tivated lymphocytes were used. Fig. 1G shows the histogram of
these three populations analyzed. By one hand NKDC expressed
higher levels of IL-21R than pDC that did not grow with IL-21, by
the other hand unactivated lymphocytes did not express IL-21R
compared with pDC and NKDC. The MFI of IL-21R for NKDC cells
was 24.95, for pDC it was 10.78 and for lymphocytes it was 4.27.
This data indicates that the fresh population of NKDC, inside total
isolated CD11c+ from spleen expresses IL-21R and it is ready to re-
spond to recombinant IL-21.
3.3. IL-21 expanded NKDC produces IFN-c in vitro
We observed that addition of IL-21 in a culture of splenic puri-
ﬁed CD11c+ cells stimulated the expansion of NKDCs. Because one
of the main characteristics of these cells is the production of IFN-c,
we investigated if the expanded NKDC with IL-21 would also pro-
duce IFN-c. An intracellular staining experiment was performed
using total cells recovered after expansion. When cells were cul-
tured only with media and saline, 18.4% from CD11clow/meB220+
NK1.1+ (NKDC) were IFN-c positive (Fig. 2A). The addition of re-
combinant IL-21 in the culture lead to a slight increase in this pop-
ulation, since when 10 ng/ml was used the percentage of NKDC
IFN-c+ cells increased from 18.4% to 24.6%. When a concentration
20 ng/ml was used NKDC IFN-c+ increased to 32.7%. The fold
increasing for 10 ng/ml and 20 ng/ml of IL-21 were 1.3 and 1.8,
respectively, however, only the concentration of 20 ng/ml in-
creased signiﬁcantly (Fig. 2B). This data indicate that NKDCs ex-
panded with IL-21 in vitro produced IFN-c.
3.4. NKDC expanded with interleukin-21 kills B16B10 tumor cells
in vitro and reduce the growth of the tumor in vivo
Our data indicated that NKDC were expanded from a culture of
splenic CD11c+ with IL-21. In order to show that these expanded
NKDCs directly kill the tumor cells we used an in vitro CFSE-based
cytotoxic assay with B16F10 tumor cells line as a target. As shown
in Fig. 3A there was a reduction in B16F10 CFSE+ cells when they
were incubated with NKDC expanded with IL-21, and even though
there was no signiﬁcant difference between cells treated with
10 ng or 20 ng of IL-21, a slight reduction with the higher dose of
IL-21 was observed.
We then investigated if NKDC recovered after IL-21 treatment
could also inhibit the growth of B16F10 tumors in vivo. In order
to do that, B16F10 cell were injected subcutaneously in the right
thigh in C57BL/6 mice. Four days after injection, mice were treated
with 1  105 NKDC recovered from cultures with media or media
supplemented with IL-21 (10 ng/ml or 20 ng/ml) intratumorally.
The leg volume was analyzed every three days. Up until the 15th
day after injection we did not observe any difference betweenthe groups. However, after 20 days, tumor growth was clearly im-
paired in the group of mice that were treated in the tumor site with
NKDC stimulated with 10 ng/ml or 20 ng/ml of IL-21, compared
with the group of mice treated with NKDC cultured only with med-
ia (Fig. 3C–E). The mean tumor volume was 326.1 mm3 in the
group treated with NKCDs cultured with 20 ng/ml of IL-21, while
the mean volume was 1646.1 mm3 in NKDC untreated group
(Fig. 3F), a 5 fold signiﬁcant difference. This result indicated that
a preparation of cells in which NKDC were stimulated and enriched
with IL-21 has anti-tumoral effect.4. Discussion
In this report we showed that IL-21 increases the numbers of
NKDCs in a splenic DC culture and the expanded cells also im-
proved the antitumor activity against B16F10 tumor cells.
Although this is an already terminally differentiated population,
treatment with this cytokine increased frequency of these cells
in vitro and they are also producing IFN-c. To our knowledge, this
is the ﬁrst study that evaluated the action of IL-21, the most re-
cently described member from c-chain user family, over NKDC,
both in vitro and in vivo.
For characterization of NKDC we set up a combination of cells
markers. The NKDCs were characterized as CD11clow/medB220+-
NK1.1
+
since CD11c is highly expressed on DC populations. B220
is always expressed by NKDC and NK1.1 is the marker that these
cells share with NK cells. To characterize NKDC, others have previ-
ously used different combinations of markers. Ullrich and colabo-
rators characterized these cells as CD3-CD11c+B220+NK1.1+;
Himoudi used CD11cintB220+CD49+ [24]; Vosshenrich used
CD11clowB220+ [25]; Geurtsvankessed considered NKDC as
CD11cintB220+Nk1.1+ [26] and Plitasused CD3-CD11c+NK1.1+ [27].
However, NKDCs are better characterized as a population that ex-
press low or intermediate levels of CD11c, high expression levels
are more appropriated to characterize conventional DCs instead
of NKDCs [25,28].
Our ﬁndings indicate that the small splenic population of
NKDCs was increased by about four times after in vitro culture of
freshly isolated CD11c+ with IL-21 (0.985% vs 3.66%). This increase
is related to the dependence of NKDC from cytokines that use the
c-chain subunit for proliferation and growth, especially IL-15. Pre-
vious studies have reported that in vivo treatment with this cyto-
kine increased the number of NKDCs in about 50%. Chaudhry and
collaborators also showed that in mice knockout to IL-15 gene
the percentage of splenic NKDC are even less than 0.5% from total
CD11c, implying that these cells are dependent on IL-15 to exist.
Injection of IL-15 increased the number of splenic NKDCs in about
3-fold over the baseline [15,30]. Interleukin-2, another c-chain
cytokine, also induces proliferation and anti-tumor activity of
NKDCs in vivo, when combined with imatinib mesylate, a drug
for stromal gastrointestinal cancer [28]. However, culture of NKDC
with IL-2 resulted in <20% cells viability by day 3 and near com-
plete cell loss on day 7 [15]. Taken together, these studies indicate
that any procedure to increase the NKDC population or function
should consider the use of a c-chain cytokine, as we did using
IL-21 to induce these cells. We believe that the previous aspects
observed with IL-15 corroborate our observation that NKDC can
proliferate in response to IL-21 in vitro.
To conﬁrm if the effect observed on NKDCs was a result from di-
rect binding of IL-21 on the cell surface and not from any bystander
action of another cell or factor released during the stimulation, we
investigated if IL-21R was expressed on expanded NKDC. The pDCs
were deﬁned as CD11clowB220+NK1.1 and were used as negative
control for expansion with IL-21 and analysis of IL-21R expression.
We favored the use of pDC instead of NK cells as negative control
Fig. 2. IFN-c production by NKDC: splenocytes were isolated from C57BL/6 mice and CD11c+ cells isolated with immunomagnetic beads. Cells were cultured in DMEM
1  10% SFB with or without IL-21 (10 or 20 ng/ml) for four days. The IFN-c was determined by intracellular staining. The cells were stained for surface marker CD11c, B220,
NK1.1, and intracellular stained for IFN-c. (A) Contour plot of NKDC IFN-c+ cells treated only with media/saline (18.4%), 10 ng/ml (24.6%) and 20 ng/ml (32.7%) of IL-21. (B)
Percentage of NKDC IFN-c+ in all untreated and treated groups; These data represent the mean ± standard error of two independent experiments.p < 0.05.
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CD11b) and arise from close related progenitors [32]. The results
showed that freshly puriﬁed NKDC expressed more IL-21R on cell
surface than pDC. This observation explains why they respond
more efﬁciently to IL-21 treatment. The magnitude of the pDC pop-
ulation did not change with any dose of IL-21 used, possibly be-
cause they do not express signiﬁcant quantities of IL-21R. We did
not perform any experiment to investigate if IL-21 induces activa-
tion of NKDC in vitro, but the presence of IL-21R on freshly isolated
cells indicated that they are ready to respond to this cytokine.
These observations suggest a direct effect from the cytokine on
the cell surface instead of a bystander effect from other factor pres-
ent in culture.
We also observed that our expanded NKDCs are producing IFN-
c in vitro. The amount of IFN-c detected after expansion with IL-21
is too low to represent a dose dependent increase, however this
analysis corroborates the characterization of IFN-c producing
NKDC. IFN-c is one of the most reliable markers to indicate effector
function of CD8+ and NK cells, and mice deﬁcient in IFN-c or its
receptor are susceptible to infection with intracellular bacteria
and virus [33,34]. NKDC produces high amounts of IFN-c compared
with NK cells in murine models of tumor and bacterial infection.
The combination of IL-18 with IL-12 was the most potent inducer
of IFN-c by NKDC in vitro. IFN-c is only seen after the incubation of
IL-15 pre-treated cells with IL-12 and IL-18 [27,35]. Interleukin-15
improves the response of NKDC to other cytokines, and does not di-
rectly increase the production of IFN-c in vitro [15]. In our experi-ments with IL-21 we also did not see a signiﬁcant improvement of
IFN-c production with IL-21 alone, in agreement with those
ﬁndings.
Direct intratumoral injection of puriﬁed IL-21 expanded CD11c+
cells abrogated B16F10 tumor growth in C57BL/6 mice. Also,
twenty days after injection of IL-21 expanded NKDCs cells into
the growing tumor, we observed a signiﬁcant decrease in leg vol-
ume between the group of animals injected only with NKDC trea-
ted with the high dose of IL-21 (20 ng/ml) compared with those
injected with untreated NKDC. Administration of IL-21 in tumor
bearing mice induces the inﬁltration of NK cells into the tumor, fol-
lowed by antigen speciﬁc CD8+ T cells, however the role of this
cytokine in lymphocyte function during tumor immune responses
is more restricted to cells housed in the lymphoid organs and anti-
gen-speciﬁc T cells [38,39]. Several studies have explored the anti-
tumoral potential of NKDCs and most of them used cytokines from
innate immunity to optimize the function of these cells [12,30,31].
However if NKDCs can inﬂuence adaptive immunity, as several
previous studies have claimed this hypothesis, independently if
they present antigen or not it could be predicted that they should
also respond to cytokines produced by activated T cells. Indeed,
normally T cells located inside the tumor are inefﬁcient to modu-
lating an immunological response [36,37], so the surrounding T
cells outside the tumor should be activated and they need tumor
fragments to start the adaptive immunity. NKDC can ﬁrst attach
to the tumor, generate and present fragments to T cells that
become activated and produce IL-21. The importance of the anti-
Fig. 3. In vitro cytotoxicity against B16F10 tumor cells and Inhibition of tumor growth with expanded NKDC. B16F10 cells were stained with CFSE (target cells) and cultured
with NKDC (effectors cells) (6  104) stimulated with IL-21 (10 or 20 ng/ml) at different ratios of effectors and target cells E/T 1:6 (1  104); 1:12 (0.5  104) and 1:24
(0.25  104). (A) Contour plot of CFSE+B16F10 cells cultures with NKDC untreated or treated with 10 ng/ml or 20 ng/ml of IL-21; ratio 1:6. (B) Percentage of CFSE + B16F10
cells after culture of NKDC stimulated with 10 or 20 ng/ml and different ratios of effector:target cells. B16F10 cells were cultured till conﬂuence and 1  106 cells were
injected in subcutaneously in the right thigh using PBS as vehicle, 100 ll by leg. Four days, in the beginning of tumor growing mice were treated with NKDC expanded with
10 ng/ml or 20 ng/ml of IL-21. Fifteen and twenty days after treatment the leg volume was analyzed considering tumor volume (V) (mm3); V = d2  D  0.5, where d = minor
diameter and D = major diameter. (C) Leg from mouse treated with NKDC expanded in media only. (D) Leg from mouse treated with NKDC expanded in media supplemented
with 10 ng/ml of IL-21. (E) Leg from mouse treated with NKDC expanded in media supplemented with 20 ng/ml of IL-21. (F) Blank: cells cultured only with media; black: IL-
21 10 ng/ml; lined: IL-21 ng/ml. These data represent the mean ± standard error of two independent experiments.p < 0.05.
A.P. Souza et al. / Cytokine 61 (2013) 154–160 159tumor effect of NKDC was previously observed when these cells
were removed from bone marrow generated DC and the tumorici-dal effect was totally lost; when the cells were added back, the ef-
fect was restored [24].
160 A.P. Souza et al. / Cytokine 61 (2013) 154–160In conclusion, our results support the idea that murine IL-21 can
be applied as a proliferative factor for speciﬁcally increasing
NKDCs inside a population of splenic CD11c+ cells. The expanded
cells also maintained phenotypic and effector characteristics. As
the anti-tumor action is an intrinsic effector activity of NKDCs,
the use of IL-21 to optimize the generation of NKDCs is relevant
for development new anti-tumor therapies.
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